EGFR and lung adenocarcinoma: For the first time, a study evaluated a dual EGFR-TKI approach, combining gefitinib (an EGFR inhibitor) with nilotinib, in patients with EGFR-mutated lung adenocarcinoma and Bcr-Abl1-positive CML.